Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PARG | Q86W56 | 2/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | PCK1 | P35558 | 2/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPRG | P23470 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862506 | 0.87 | KMT2A (0.41) | PPARGKMT2AMEN1PARGPCK1 | |
| SCHEMBL831842 | 0.85 | KMT2A (0.39) | KMT2AMEN1PARGPCK1ECE1 | |
| SCHEMBL832157 | 0.84 | KMT2A (0.38) | KMT2AMEN1PARGPCK1PTGDR2 | |
| SCHEMBL829588 | 0.82 | PPARG (0.44) | PPARGKMT2AMEN1PARGKAT6A | |
| SCHEMBL12665499 | 0.82 | KMT2A (0.45) | KMT2AMEN1PTGDR2 | |
| SCHEMBL831414 | 0.81 | PPARG (0.42) | PPARGKMT2AMEN1PARGKAT6A | |
| SCHEMBL831747 | 0.81 | PTGER3 (0.38) | PPARGKMT2AMEN1PARGPTPRG | |
| SCHEMBL831401 | 0.79 | PTGDR2 (0.38) | PPARGPTGDR2 | |
| SCHEMBL831757 | 0.79 | PTGDR2 (0.38) | PPARGPTGDR2 | |
| SCHEMBL862184 | 0.79 | PPARG (0.39) | PPARGKMT2AMEN1PARGPCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | PPARG 4093/4885KMT2A 321/4885MEN1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.